{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-005986","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.746435+00:00","generated_at":"2026-06-05T07:17:09.713925+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Clene reports positive long-term results from VISIONARY-MS LTE trial for CNM-Au8 in MS","bullets":["Long-term CNM-Au8 treatment showed significant improvement in vision (LCLA) through 35 months, p<0.0001, mean +8.70 letters.","Cognition improved via SDMT through 35 months, p<0.0001, mean +8.03 points.","Global neurological function (mMSFC) improved through 35 months, p=0.018.","No serious adverse events attributed to CNM-Au8; treatment well-tolerated with 94% compliance.","Data presented at ACTRIMS Forum 2024; 55 of 69 eligible participants continued in LTE."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-005986","json":"https://secwatch.observer/filing/0001437749-24-005986.json","markdown":"https://secwatch.observer/filing/0001437749-24-005986.md","text":"https://secwatch.observer/filing/0001437749-24-005986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924005986/0001437749-24-005986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924005986/clnn20240228_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:17:09.713925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}